Continued growth in shareholder payouts

  • Amgen raises dividend by 5.6% to $2.25 a share
  • 12th consecutive year of increased payout to shareholders
  • Dividend payable on March 7 to shareholders of record on Feb. 16
  • Annual yield of 3.3% based on Tuesday’s closing price

Amgen, the pharmaceutical company based in Thousand Oaks, California, has announced a 5.6% increase in its dividend, marking the 12th consecutive year of increased payout to shareholders. The first-quarter dividend will be $2.25 per share, up from the previous dividend of $2.13 per share. With an annual yield of 3.3% based on Tuesday’s closing price of $273.99 per share, the dividend will be payable on March 7 to shareholders of record on February 16. Despite regular dividend raises, Amgen remains committed to investing in innovation and reducing its debt.

Public Companies: Amgen (AMGN)
Private Companies:
Key People:

Track all markets on TradingView

Factuality Level: 9
Justification: The article provides factual information about Amgen raising its dividend by 5.6% and the details of the dividend payout. There are no digressions, misleading information, sensationalism, redundancy, or opinion masquerading as fact. The article is concise and sticks to the main topic without unnecessary background information. There is no bias or personal perspective presented as universally accepted truth. The information provided is consistent and does not contain any logical errors, fallacies, or incorrect conclusions.

Noise Level: 7
Justification: The article provides information about Amgen raising its dividend by 5.6% and mentions that it is the company’s 12th consecutive year with an increased payout to shareholders. However, it lacks analysis or insights into the long-term trends or consequences of this decision. It also does not provide any evidence or data to support its claims. The article stays on topic but does not offer any actionable insights or solutions. Overall, the article contains mostly factual information without much depth or analysis, resulting in a higher noise level.

Financial Relevance: Yes
Financial Markets Impacted: Pharmaceutical industry

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article pertains to financial topics as it discusses Amgen’s dividend increase and its impact on shareholders. However, there is no mention of any extreme events or their impact.

Reported publicly: www.marketwatch.com